Share on LinkedInShare on LinkedIn

ARTICLE · 16 NOVEMBER 2026

Competition Currents | November 2026

Greenberg Traurig
Greenberg Traurig
Contributor
Greenberg Traurig

Greenberg Traurig

Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States,...

View firm profile
Explore more from Greenberg Traurig

This comprehensive global antitrust newsletter examines major competition law developments across seven jurisdictions, including landmark enforcement actions, merger reviews, and regulatory initiatives. From record-breaking penalties in China's online travel sector to groundbreaking guidelines on algorithmic pricing and abuse of dominance, the update covers critical developments shaping international competition policy and enforcement priorities.

United StatesAntitrust/Competition Law

In This Issue1

United States | Mexico | China | Poland | The Netherlands |
European Union | Italy

United States

A. U.S. Litigation

1. In re: Lantus Direct Purchaser Antitrust Litigation, Case No. 1:16-cv-12652 (D. Mass.)

On Oct. 27, 2026, Sanofi-Aventis U.S. and a group of drug wholesalers informed a Massachusetts federal court that they had agreed to resolve antitrust claims alleging that Sanofi improperly listed patents covering components of its Lantus SoloStar insulin pen in the FDA’s Orange Book to delay competing products. The settlement avoids a January trial and follows the court’s decision earlier this year denying cross-motions for summary judgment, in which the court found that although the patents should not have been listed in the Orange Book, a jury should decide whether Sanofi’s listings unlawfully restrained competition.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from